GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10‐Year Population‐Based Study
Open Access
- 2 February 2022
- journal article
- research article
- Published by Wiley in Movement Disorders
- Vol. 37 (5) , 1016-1027
Abstract
Background: Common genetic variance in apolipoprotein E (APOE), β‐glucocerebrosidase (GBA), microtubule‐associated protein tau (MAPT), and α‐synuclein (SNCA) has been linked to cognitive decline in Parkinson's disease (PD), although studies have yielded mixed results.Objectives: To evaluate the effect of genetic variants in APOE, GBA, MAPT, and SNCA on cognitive decline and risk of dementia in a pooled analysis of six longitudinal, non‐selective, population‐based cohorts of newly diagnosed PD patients.Methods: 1002 PD patients, followed for up to 10 years (median 7.2 years), were genotyped for at least one of APOE‐ε4, GBA mutations, MAPT H1/H2, or SNCA rs356219. We evaluated the effect of genotype on the rate of cognitive decline (Mini‐Mental State Examanation, MMSE) using linear mixed models and the development of dementia (diagnosed using standardized criteria) using Cox regression; multiple comparisons were accounted for using Benjamini−Hochberg corrections.Results: Carriers of APOE‐ε4 (n = 281, 29.7%) and GBA mutations (n = 100, 10.3%) had faster cognitive decline and were at higher risk of progression to dementia (APOE‐ε4, HR 3.57, P < 0.001; GBA mutations, HR 1.76, P = 0.001) than non‐carriers. The risk of cognitive decline and dementia (HR 5.19, P < 0.001) was further increased in carriers of both risk genotypes (n = 23). No significant effects were observed for MAPT or SNCA rs356219.Conclusions: GBA and APOE genotyping could improve the prediction of cognitive decline in PD, which is important to inform the clinical trial selection and potentially to enable personalized treatment © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder SocietyKeywords
Funding Information
- Academy of Medical Sciences
- Bupa Foundation
- European Research Council
- Helse Vest (911218)
- Hjärnfonden
- John and Lucille Van Geest Foundation
- Kempestiftelserna
- Knut och Alice Wallenbergs Stiftelse
- Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
- Medical Research Council Canada
- Medicinska Forskningdet
- National Institutes of Health (NINDS/NIA R01NS115144, U01NS095736, U01NS100603)
- NIHR Cambridge Biomedical Research Centre (BRC‐1215‐20014)
- Norges Forskningsråd (177966, 287842)
- Nasjonalforeningen for Folkehelsen
- Parkinson's UK (G‐0502, G‐0914, G‐1301, G‐1302, G‐1507, J‐0802)
- Springfield Foundation
- Umeå Universitet
- Västerbotten Läns Landsting
- Wellcome Trust
This publication has 56 references indexed in Scilit:
- Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society‐unified Parkinson's disease rating scale scoresMovement Disorders, 2012
- Genetic influences on cognitive decline in Parkinson's diseaseMovement Disorders, 2012
- A recommended scale for cognitive screening in clinical trials of Parkinson's diseaseMovement Disorders, 2010
- Incidence of Parkinson's disease and parkinsonism in northern Sweden: A population‐based studyMovement Disorders, 2010
- Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's diseaseBrain, 2009
- Lack of association of APOE and tau polymorphisms with dementia in Parkinson’s diseaseNeuroscience Letters, 2008
- Tau and α‐synuclein in susceptibility to, and dementia in, Parkinson's diseaseAnnals of Neurology, 2007
- Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodiesJournal of Neurology, Neurosurgery & Psychiatry, 2006
- Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementiaMovement Disorders, 2005
- ParkinsonismNeurology, 1967